Avalon GloboCare Corp. (NASDAQ:CHGA) Sees Significant Drop in Short Interest

Avalon GloboCare Corp. (NASDAQ:CHGA) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 68,808 shares, a decline of 69.7% from the August 15th total of 226,852 shares. Currently, 9.6% of the company’s shares are short sold. Based on an average daily volume of 723,976 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Avalon GloboCare Stock Down 0.9%

Shares of Avalon GloboCare stock traded down $0.02 during trading on Friday, reaching $2.23. The company’s stock had a trading volume of 21,781 shares, compared to its average volume of 409,124. The company has a 50-day simple moving average of $4.76 and a two-hundred day simple moving average of $7.94. Avalon GloboCare has a 1-year low of $2.15 and a 1-year high of $57.97. The company has a market cap of $2.12 million, a price-to-earnings ratio of -0.16 and a beta of -0.05.

Avalon GloboCare (NASDAQ:CHGA) last announced its quarterly earnings data on Friday, August 14th. The company reported ($2.80) EPS for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.